Investors walked away from shares of Minerva Neurosciences (NASDAQ: NERV) and Axsome Therapeutics (NASDAQ: AXSM) last month. OK, it was more of a sprint. The stock prices of the pair have fallen 33% and 29%, respectively, since the beginning of September, but each tumbled for a different reason.
Considering the companies have big plans for their late-stage drug candidates, investors with a long-term mindset might be wondering if the recent share price declines present a buying opportunity. Is either one of these small-cap pharmaceutical stocks a buy?
Image source: Getty Images.